



2026 Q1 Results

Asymchem Laboratories (Tianjin) Co., Ltd.

002821.SZ/6821.HK

This document is not for public dissemination and the information contained herein is for the exclusive use of the persons to whom it is addressed and their advisers in connection with Asymchem Laboratories (Tianjin) Co., Ltd. (the “**Company**”, together with its subsidiaries, hereinafter referred to as the “**Group**”). It is being made available by the Company to a limited number of recipients. The contents of this document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and whoever comes into possession of this document should inform themselves about, and observe such restrictions. Any failure to comply with this restriction may constitute a violation of the United States, Canadian, PRC or Japanese securities laws or the laws of any such other jurisdictions. By accepting this document, you agree to be bound by the foregoing limitations.

Forward-Looking Statement

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients’ intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

All financials disclosed in this document are presented in accordance with International Financial Reporting Standards (“**IFRS**”s) except for those specifically noted otherwise.

Use of Adjusted Financial Measures

We have provided adjusted net profit attributable to shareholders of the Company and adjusted net profit margin attributable to shareholders of the Company as additional financial measures, which are not required by, or presented in accordance with, the IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that we do not consider indicative of the performance of our business. However, the presentation of these non- IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS.

1,802

Q1 Revenue (RMB mm)



+16.9%

@CER²: +19.5%

42.7%

Gross Profit Margin



+0.5pts³

@CER: +1.7pts

Small Molecule CDMO Business

Revenue

Upward momentum

@CER: +3.3%

Gross Profit Margin

46.3%



+1.4pts

@CER: +2.9pts

304

Net Profit Attributable to Shareholders of the Listed Company (RMB mm)

(6.8%)

423

Adjusted Net Profit Attributable to Shareholders of the Listed Company (RMB mm)



+27.9%

Emerging Business

Revenue

RMB598mm



74.1%

Gross Profit Margin

35.0%



+2.3pts


@CER: +3.1pts

The Company has continued to increase its investment in technology R&D, capability enhancement and capacity expansion for modalities such as peptides, oligonucleotides and ADCs

In 2026Q1, revenue from U.S. and European markets amounted to **RMB1,250mm**, demonstrating a yoy increase of **9.0%**, or **12.4%** @CER, while revenue from the Asia-Pacific⁴ market amounted to **RMB552mm**, reflecting a yoy increase of **40.0%**


RMB mm	2026Q1	2025Q1
Net Profit Attributable to Shareholders of the Listed Company	304	327
Add:		
Amortization Expenses of Share-based Compensation	19	7
Gain or Loss on Exchange Rate Fluctuations	126	(4)
Income Tax Effect	(26)	0
Adjusted Net Profit Attributable to Shareholders of the Listed Company	423	330
Adjusted Net Profit Margin Attributable to Shareholders of the Listed Company	23.5%	21.4%

Adjusted Net Profit Attributable to Shareholders of the Listed Company




2026 Q1 Expenses for the Period


Selling and Distribution Expenses as % of Total Revenue




Administrative Expenses* as % of Total Revenue




R&D Expenses as % of Total Revenue



Finance Costs* as % of Total Revenue



*Due to the disparities between Chinese Accounting Standards ("CAS") and International Financial Reporting Standards ("IFRS"), there exist variations in the treatment of administrative expenses and finance costs. Consequently, under IFRS, these expenses differ from those recognized under CAS. To accurately represent the concept of "net finance costs," we have chosen to utilize finance costs as per CAS. This entails including exchange gains, bank interest income, bank charges, and other expenses/gains derived from financing activities.






The CDMO industry has shown a positive trend. After the Company returned the growth trajectory in 2025, orders will continue to grow while operation will remain favorable. The Company expects its operating performance in 2026 to show an accelerated growth trend with **estimated revenue growth of 19-22%**

In 2026, the Company will vigorously promote the development of emerging businesses such as chemical macromolecules and biological macromolecules CDMO businesses, firmly seizing market opportunities to continuously generate incremental contributions in these areas. Meanwhile, it will promote the steady development of small molecule business, laying a solid foundation for sustained growth in performance

Focusing on improving operational efficiency, the strategy will shift from cost reduction and efficiency enhancement to cost control and efficiency improvement, effectively increasing profit margins and business competitiveness

In light of the Company's sustained business momentum, it will proactively advance capacity expansion, with Capex for 2026 projected at around RMB 2.1 billion

Appendix



CONSOLIDATED STATEMENT OF PROFIT OR LOSS

RMB mm

	2026 Q1	2025 Q1
Revenue	1,802	1,541
Cost of sales	(1,033)	(891)
Gross profit	769	650
Other income and gains	95	87
Selling and distribution expenses	(51)	(44)
Administrative expenses	(216)	(191)
Research and development expenses	(127)	(138)
Net impairment losses on financial and contract assets, net	(6)	2
Other expenses	(130)	(6)
Finance costs	(3)	(3)
Share of profit/(loss) of associates	2	0
Profit before tax	333	357
Income tax expense	(32)	(32)
Profit for the period	301	325
Attributable to:		
Owners of the parent	304	327
Non-controlling interests	(3)	(2)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

RMB mm

	2026 Q1	2025
Non-current assets		
Property, plant and equipment	6,649	6,442
Right-of-use assets	651	669
Goodwill	146	146
Other intangible assets	25	25
Deferred tax assets	280	276
Investments in associates	553	573
Prepayments, deposits and other receivables	476	446
Financial assets at fair value through profit or loss	194	194
Total non-current assets	8,974	8,771
Current assets		
Inventories	1,621	1,471
Trade receivables	1,879	1,977
Contract assets	75	83
Prepayments, deposits and other receivables	375	523
Tax recoverable	2	14
Financial assets at fair value through profit or loss	1,049	1,117
Cash and bank balances	6,730	6,321
Total current assets	11,731	11,506
Total assets	20,705	20,277

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(continued)

	2026 Q1	2025
Current liabilities		
Trade payables	596	584
Other payables and accruals	1,371	1,247
Financial liabilities at fair value through profit or loss	6	10
Lease liabilities	54	53
Tax payable	30	69
Amounts due to related parties	4	5
Total current liabilities	2,061	1,968
Non-current liabilities		
Deferred income	307	295
Lease liabilities	239	256
Deferred tax liabilities	136	112
Total non-current liabilities	682	663
Equity		
Share capital	361	361
Treasury shares	(836)	(838)
Reserves	18,428	18,113
Non-controlling interests	9	11
Total equity	17,962	17,646



Thanks!

